Li Zhiming
Li Zhiming
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Not yet recruiting | Phase 2 | 2025-11-19 | NCT07231250 | |
| Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL | BTKi; CD20; Initial MZL; Untreated MZL | Recruiting | Phase 2 | 2025-05-22 | NCT06985472 | |
| Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL | BTK Inhibitors; Double Express Diffuse Large B-cell Lymphoma; Histone Deacetylase Inhibitor | Not yet recruiting | Phase 2 | 2025-03-24 | NCT06890585 |